Home›Asciminib

Asciminib

Also known as: Scemblix

Route: Oral

4 interactions on record

Asciminib has 4 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Itraconazole Oral Solution Containing Hydroxypropyl-β-Cyclodextrin, Rosuvastatin, Itraconazole. Patients taking Asciminib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 4
Contraindicated: 2
Major: 2

Contraindicated (2)

Asciminib + Itraconazole Oral Solution Containing Hydroxypropyl-β-Cyclodextrin— Concomitant use decreases asciminib Cmax and AUC, which may reduce SCEMBLIX efficacy. Avoid coadministration at all reco…
Asciminib + Rosuvastatin— Avoid concomitant use of SCEMBLIX at all recommended doses due to increased risk of rosuvastatin adverse reactions.

Major (2)

Asciminib + Itraconazole— ( 7.1 ) Itraconazole Oral Solution Containing Hydroxypropyl-β-cyclodextrin: Avoid concomitant use of SCEMBLIX at all rec…
Asciminib + Mao Inhibitors— Increases asciminib Cmax and AUC, which may increase risk of adverse reactions. Closely monitor during concomitant use a…

Asciminib + Itraconazole Oral Solution Containing Hydroxypropyl-β-Cyclodextrin⛔Contraindicated

Concomitant use decreases asciminib Cmax and AUC, which may reduce SCEMBLIX efficacy. Avoid coadministration at all recommended doses.

Asciminib + Rosuvastatin⛔Contraindicated

Avoid concomitant use of SCEMBLIX at all recommended doses due to increased risk of rosuvastatin adverse reactions.

Asciminib + Itraconazole⚠️Major

( 7.1 ) Itraconazole Oral Solution Containing Hydroxypropyl-β-cyclodextrin: Avoid concomitant use of SCEMBLIX at all recommended doses. Itraconazole Oral Solution Containing Hydroxypropyl-β-cyclodextrin Concomitant use of SCEMBLIX with itraconazole oral solution containing hydroxypropyl-β-cyclodextrin decreases asciminib C max and AUC, which may reduce SCEMBLIX efficacy [see Clinical Pharmacology (12.3)] . Avoid coadministration of SCEMBLIX at all recommended doses with itraconazole oral solution containing hydroxypropyl-β-cyclodextrin.

Asciminib + Mao Inhibitors⚠️Major

Increases asciminib Cmax and AUC, which may increase risk of adverse reactions. Closely monitor during concomitant use at 200 mg twice daily.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.